Doug Ford's 'Buy Ontario' Act Puts Healthcare at Risk in Trade War
Ontario Premier Doug Ford assumed the role of Captain Canada last winter when U.S. President Donald Trump imposed harsh tariffs on Canada's economy, filling a leadership void at the federal level. Ford frequently appeared on American television, advocating passionately for free and open trade between the two nations as essential for mutual economic success.
From Free Trade Advocate to Protectionist Policies
However, as Trump entrenched his tariff policies, Ford has increasingly adopted measures that mirror American protectionism. His response to U.S. trade barriers appears to be a form of Canadian protectionism, raising concerns about its impact on critical sectors.
One key initiative from the Ford government is the Buy Ontario Act, 2025, which mandates public sector organizations to prioritize goods and services from Ontario and then Canada. While strengthening domestic supply chains is a logical goal, this policy could have severe repercussions, particularly in healthcare.
Healthcare Sector Faces Dire Consequences
Implementing a Buy Ontario procurement policy in healthcare might force hospitals to purchase inferior or more expensive products simply because they are locally made. This comes at a time when the Ford government has labeled healthcare costs as unsustainable, potentially exacerbating financial strains.
Moreover, many vital technologies, such as cardiac implants, diagnostic equipment, and surgical robotics, lack Ontario-based alternatives. Hospitals could face critical shortages if suitable Canadian products are unavailable, jeopardizing patient care and system stability.
Rising Shortages and Administrative Burdens
Recent data indicates a 19% increase in medical device shortages in Canada during 2024-25 compared to the previous year. Restrictive procurement rules threaten to worsen this shortage crisis, increasing risks of service disruptions and deterring investment in the health sector.
Additionally, medical technology often involves components from multiple countries. Determining whether a product qualifies as Ontarian or Canadian under the new rules will introduce administrative delays and red tape, further burdening an already regulated industry.
Dependence on U.S. Imports and Retaliation Risks
Canada currently imports 40% of its medical technology from the United States. The Buy Ontario Act requires U.S. companies to have at least 250 employees in Canada to qualify, excluding most medical device firms even with a Canadian presence. This could hinder access to cutting-edge technology, harming patients.
There is also a significant risk of U.S. retaliation. With 73% of Canada's medical device exports going to the United States, if the Trump administration perceives Ford's policies as restricting access to American technology, it might retaliate, endangering Canadian exports and further destabilizing the healthcare supply chain.
Call for Policy Revisions
When loved ones require hospital care, families expect the best available technology, regardless of its origin. The Ford government must recognize that the Buy Ontario Act could detrimentally impact healthcare outcomes. This legislation needs serious revisions or outright repeal, serving as a cautionary tale for other provinces not to sacrifice health security for political gains in trade disputes.
